Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin

Annals of Hematology

Volumn 89, Issue 2, 2010, Pages 121-125

  Nachnani, Jagdish S ^a   Rao, Gowtham A ^b   Bulchandani, Deepti ^b   Pandya, Prashant K ^b   Alba, Laura M ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hematological abnormalities; Hepatitis C; Interferon; Ribavirin

Indexed keywords

CREATININE; HEMOGLOBIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT; INTERFERON;

ADULT; ANEMIA; ARTICLE; DRUG SAFETY; FEMALE; GENOTYPE; HEMATOLOGIC DISEASE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; BLOOD; CHEMICALLY INDUCED DISORDER; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR;

ADULT; ANEMIA; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEMATOLOGIC DISEASES; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; RIBAVIRIN; RISK FACTORS; THROMBOCYTOPENIA;

EID: 74049101178     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0774-y     Document Type: Article

References (17)

1. Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29 (Suppl 1):74-81.
2. Hoofnagle JH (1997) Hepatitis C: the clinical spectrum of disease. Hepatology 26:15S-20S.
3. Kew MC (1998) Hepatitis viruses and hepatocellular carcinoma. Res Virol 149:257-62.
4. Yoshida H, Arakawa Y, Sata M et al (2002) Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123:483-91.
5. McHutchison JG, Ware JE Jr, Bayliss MS et al (2001) The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 34:140-7.
6. Fried MW, Shiffman ML, Reddy KR et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-82.
7. Manns MP, McHutchison JG, Gordon SC et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-65.
8. McHutchison JG, Manns MP, Brown RS Jr et al (2007) Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 102:880-9.
9. McHutchison JG, Manns M, Patel K et al (2002) Adherence to combination therapy enhances sustained response in genotype-1- infected patients with chronic hepatitis C. Gastroenterology 123:1061-9.
10. Reau N, Hadziyannis SJ, Messinger D et al (2008) Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol 103:1981-8.
11. Mulhall BP, Younossi Z (2005) Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 39:S23.
12. Ong JP, Younossi ZM (2004) Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 71(Suppl 3):S17-S21.
13. Kowdley KV (2005) Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 39:S3-S8.
14. www.rocheusa.com. Package insert Ribavirin.
15. Roche(Pegasys). Accessed from package insert.
16. PEGINTRON. Package insert.
17. Idrees M, Riazuddin S (2009) A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 9:5.